Pharmacotherapy for the prevention of post-ERCP pancreatitis

Erina Foster; Joseph Leung

doi:10.1111/j.1572-0241.2006.00950.x

Pharmacotherapy for the prevention of post-ERCP pancreatitis

Erina Foster, Joseph Leung

Gastroenterology and Hepatology

Research output: Contribution to journal › Article

14 Scopus citations

Abstract

Post-ERCP pancreatitis (PEP) is a potential complication of ERCP. Pharmacotherapy for prevention of PEP aims at reducing basal sphincter pressure and contractility or a decrease in pancreatic secretion to reduce intraductal pressure. Timing and route of administration of drugs are critical to ensure maximum benefits from medications. Pancreatic stenting offers an alternative to decompress the pancreas and is effective in reducing PEP in high-risk patients.

Original language	English (US)
Pages (from-to)	52-55
Number of pages	4
Journal	American Journal of Gastroenterology
Volume	102
Issue number	1
DOIs	https://doi.org/10.1111/j.1572-0241.2006.00950.x
State	Published - Jan 2007

ASJC Scopus subject areas

Gastroenterology

Access to Document

10.1111/j.1572-0241.2006.00950.x

Fingerprint Dive into the research topics of 'Pharmacotherapy for the prevention of post-ERCP pancreatitis'. Together they form a unique fingerprint.

Cite this

Foster, E., & Leung, J. (2007). Pharmacotherapy for the prevention of post-ERCP pancreatitis. American Journal of Gastroenterology, 102(1), 52-55. https://doi.org/10.1111/j.1572-0241.2006.00950.x

@article{4581fd6a685c43248fe5b717b3c67aa8,

title = "Pharmacotherapy for the prevention of post-ERCP pancreatitis",

abstract = "Post-ERCP pancreatitis (PEP) is a potential complication of ERCP. Pharmacotherapy for prevention of PEP aims at reducing basal sphincter pressure and contractility or a decrease in pancreatic secretion to reduce intraductal pressure. Timing and route of administration of drugs are critical to ensure maximum benefits from medications. Pancreatic stenting offers an alternative to decompress the pancreas and is effective in reducing PEP in high-risk patients.",

author = "Erina Foster and Joseph Leung",

year = "2007",

month = jan,

doi = "10.1111/j.1572-0241.2006.00950.x",

language = "English (US)",

volume = "102",

pages = "52--55",

journal = "American Journal of Gastroenterology",

issn = "0002-9270",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - Pharmacotherapy for the prevention of post-ERCP pancreatitis

AU - Foster, Erina

AU - Leung, Joseph

PY - 2007/1

Y1 - 2007/1

N2 - Post-ERCP pancreatitis (PEP) is a potential complication of ERCP. Pharmacotherapy for prevention of PEP aims at reducing basal sphincter pressure and contractility or a decrease in pancreatic secretion to reduce intraductal pressure. Timing and route of administration of drugs are critical to ensure maximum benefits from medications. Pancreatic stenting offers an alternative to decompress the pancreas and is effective in reducing PEP in high-risk patients.

AB - Post-ERCP pancreatitis (PEP) is a potential complication of ERCP. Pharmacotherapy for prevention of PEP aims at reducing basal sphincter pressure and contractility or a decrease in pancreatic secretion to reduce intraductal pressure. Timing and route of administration of drugs are critical to ensure maximum benefits from medications. Pancreatic stenting offers an alternative to decompress the pancreas and is effective in reducing PEP in high-risk patients.

UR - http://www.scopus.com/inward/record.url?scp=33846063359&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846063359&partnerID=8YFLogxK

U2 - 10.1111/j.1572-0241.2006.00950.x

DO - 10.1111/j.1572-0241.2006.00950.x

M3 - Article

C2 - 17266688

AN - SCOPUS:33846063359

VL - 102

SP - 52

EP - 55

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 1

ER -